Hole K, Sroga P, Nebroski M, Handel K, Lung O, Spinard E
Viruses. 2025; 16(12.
PMID: 39772222
PMC: 11680245.
DOI: 10.3390/v16121915.
Valdez F, Velazquez-Salinas L, Zhou L, Smoliga G, Fish I, Navarro-Lopez R
Microbiol Resour Announc. 2024; 14(1):e0100724.
PMID: 39670711
PMC: 11737132.
DOI: 10.1128/mra.01007-24.
Scroggs S, Swanson D, Steele T, Hudson A, Reister-Hendricks L, Gutierrez J
Viruses. 2024; 16(9).
PMID: 39339904
PMC: 11437509.
DOI: 10.3390/v16091428.
McGregor B, Rozo-Lopez P, Davis T, Drolet B
Pathogens. 2021; 10(9).
PMID: 34578160
PMC: 8471201.
DOI: 10.3390/pathogens10091126.
Pelzel-McCluskey A, Christensen B, Humphreys J, Bertram M, Keener R, Ewing R
Pathogens. 2021; 10(8).
PMID: 34451457
PMC: 8399664.
DOI: 10.3390/pathogens10080993.
Vesicular stomatitis forecasting based on Google Trends.
Wang J, Zhang T, Lu Y, Zhou G, Chen Q, Niu B
PLoS One. 2018; 13(1):e0192141.
PMID: 29385198
PMC: 5792013.
DOI: 10.1371/journal.pone.0192141.
Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice.
Zhang M, Ge J, Li X, Chen W, Wang X, Wen Z
Virol J. 2016; 13:31.
PMID: 26911572
PMC: 4765107.
DOI: 10.1186/s12985-016-0481-y.
On the possible role of robustness in the evolution of infectious diseases.
Ogbunugafor C, Pease J, Turner P
Chaos. 2010; 20(2):026108.
PMID: 20590337
PMC: 2909313.
DOI: 10.1063/1.3455189.
Biological differences between vesicular stomatitis virus Indiana and New Jersey serotype glycoproteins: identification of amino acid residues modulating pH-dependent infectivity.
Martinez I, Wertz G
J Virol. 2005; 79(6):3578-85.
PMID: 15731252
PMC: 1075735.
DOI: 10.1128/JVI.79.6.3578-3585.2005.
Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host.
Martinez I, Rodriguez L, Jimenez C, Pauszek S, Wertz G
J Virol. 2003; 77(14):8039-47.
PMID: 12829843
PMC: 161932.
DOI: 10.1128/jvi.77.14.8039-8047.2003.
Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development.
Flanagan E, Zamparo J, Ball L, Rodriguez L, Wertz G
J Virol. 2001; 75(13):6107-14.
PMID: 11390612
PMC: 114326.
DOI: 10.1128/JVI.75.13.6107-6114.2001.
